AKT1 and acute myeloid leukemia: Using combinatory assays with the anti-leukemic agent arsenic trioxide (Trisenox), we recently demonstrated that a common effect of the anti-glycolytic drugs is the stimulation (albeit with different kinetics and intensity) of Akt/mTOR and MEK/ERK defensive pathways in several human acute myeloid leukemia (AML) cell lines, and that this stimulation restrains the apoptotic efficacy of 2-DG and Lon when used as single agents [11, 12].